1. Executive Summary 2. Worldwide Number of Persons Vaccinated with Influenza Vaccines and Forecast (2013 – 2027) 3. Worldwide Influenza Vaccines Market Revenue and Forecast (2013 – 2027) 4. Worldwide Influenza Vaccines Market Share and Y–o–Y Growth (%) 4.1 Number of Persons Vaccinated with Influenza Vaccines Share,2013 – 2027(%) 4.2 Influenza Vaccines Market Share,2013 - 2027(%) 5. Worldwide Influenza Vaccines Market Drivers and Inhibitors 5.1 Market Drivers 5.2 Market Inhibitors 6. Worldwide Influenza Vaccines Market, By Geography (Volume and Value),2013 – 2027 6.1 United States 6.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.1.2 United States Influenza Vaccines Market Revenue (2013 – 2027) 6.2 Canada 6.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.2.2 Canada Influenza Vaccines Market Revenue (2013 – 2027) 6.3 Germany 6.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.3.2 Germany Influenza Vaccines Market Revenue (2013 – 2027) 6.4 France 6.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.4.2 France Influenza Vaccines Market Revenue (2013 – 2027) 6.5 Italy 6.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.5.2 Italy Influenza Vaccines Market Revenue (2013 – 2027) 6.6 Spain 6.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.6.2 Spain Influenza Vaccines Market Revenue (2013 – 2027) 6.7 United Kingdom 6.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.7.2 United Kingdom Influenza Vaccines Market Revenue (2013 – 2027) 6.8 Netherlands 6.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.8.2 Netherlands Influenza Vaccines Market Revenue (2013 – 2027) 6.9 Sweden 6.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.9.2 Sweden Influenza Vaccines Market Revenue (2013 – 2027) 6.10 Denmark 6.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.10.2 Denmark Influenza Vaccines Market Revenue (2013 – 2027) 6.11 Poland 6.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.11.2 Poland Influenza Vaccines Market Revenue (2013 – 2027) 6.12 Norway 6.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.12.2 Norway Influenza Vaccines Market Revenue (2013 – 2027) 6.13 Finland 6.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.13.2 Finland Influenza Vaccines Market Revenue (2013 – 2027) 6.14 Ireland 6.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.14.2 Ireland Influenza Vaccines Market Revenue (2013 – 2027) 6.15 Belgium 6.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.15.2 Belgium Influenza Vaccines Market Revenue (2013 – 2027) 6.16 Australia 6.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.16.2 Australia Influenza Vaccines Market Revenue (2013 – 2027) 6.17 New Zealand 6.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.17.2 New Zealand Influenza Vaccines Market Revenue (2013 – 2027) 6.18 Japan 6.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.18.2 Japan Influenza Vaccines Market Revenue (2013 – 2027) 6.19 Brazil 6.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.19.2 Brazil Influenza Vaccines Market Revenue (2013 – 2027) 6.20 China 6.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.20.2 China Influenza Vaccines Market Revenue (2013 – 2027) 6.21 India 6.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.21.2 India Influenza Vaccines Market Revenue (2013 – 2027) 6.22 Rest of the World (ROW) 6.22.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027) 6.22.2 ROW Influenza Vaccines Market Revenue (2013 – 2027) 7. Recent Development in the Worldwide Influenza Vaccines Market 8. Worldwide Influenza Vaccines Market – Regulatory System 8.1 United States 8.2 Europe 8.3 Japan 9. Major Deals in the Worldwide Influenza Vaccines Market 9.1 Merger and Acquisitions 9.2 Collaboration Deals 9.3 Licensing Agreement 9.4 Exclusive Agreement 9.5 Distribution Agreement 10. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country 10.1 Year 2020 10.2 Year 2019 11. Key Companies Analysis 11.1 Sanofi Pasteur 11.1.1 Business Overview 11.1.2 Influenza Vaccines Portfolio 11.1.3 Influenza Vaccines Value Sales Analysis 11.1.4 Promising Influenza Vaccines in the Clinical Development 11.1.5 Recent Development 11.2 GlaxoSmithKline (GSK) 11.2.1 Business Overview 11.2.2 Influenza Vaccines Portfolio 11.2.3 Influenza Vaccines Sales Value Analysis 11.2.4 Recent Development 11.3 Seqirus (CSL Limited) 11.3.1 Business Overview 11.3.2 Influenza Vaccines Portfolios 11.3.3 Influenza Vaccines Sales Value Analysis 11.3.4 Promising Influenza Vaccines in the Clinical Development 11.3.5 Recent Development 11.4 AstraZeneca 11.4.1 Business Overview 11.4.2 Influenza Vaccines Portfolio 11.4.3 Influenza Vaccines Sales Value Analysis 11.4.4 Recent Development 11.5 Gamma Vaccines Pty Ltd 11.5.1 Business Overview 11.5.2 Influenza Vaccines Portfolio 11.5.3 Recent Development 11.6 Hualan Biological Engineering Inc 11.6.1 Business Overview 11.6.2 Influenza Vaccines Portfolio 11.6.3 Recent Development 11.7 Shanghai Institute of Biological Products Co., Ltd. 11.7.1 Business Overview 11.7.2 Influenza Vaccine Portfolio 11.8 Mylan 11.8.1 Business Overview 11.8.2 Influenza Vaccine Portfolio 11.9 BioDiem 11.9.1 Business Overview 11.9.2 Influenza Vaccine Portfolio 11.9.3 Recent Development 12. Emerging Players 12.1 Novavax 12.1.1 Business Overview 12.1.2 Promising Influenza Vaccines in the Clinical Development 12.1.3 Recent Development 12.2 BiondVax Pharmaceuticals Ltd. 12.2.1 Business Overview 12.2.2 Promising Influenza Vaccines in the Clinical Development 12.2.3 Recent Development 12.3 Medicago 12.3.1 Business Overview 12.3.2 Promising Influenza Vaccines in the Clinical Development 12.3.3 Recent Development 12.4 Moderna Inc 12.4.1 Business Overview 12.4.2 Promising Influenza Vaccines in the Clinical Development 12.4.3 Recent Development 12.5 Pneumagen 12.5.1 Business Overview 12.5.2 Promising Influenza Vaccines in the Clinical Development 12.5.3 Recent Development 12.6 Altimmune 12.6.1 Business Overview 12.6.2 Promising Influenza Vaccines in the Clinical Development 12.6.3 Recent Development 12.7 Daiichi Sankyo 12.7.1 Business Overview 12.7.2 Promising Influenza Vaccines in the Clinical Development 12.7.3 Recent Development 12.8 FluGen 12.8.1 Business Overview 12.8.2 Promising Influenza Vaccines in the Clinical Development 12.8.3 Recent Development 12.9 Imutex 12.9.1 Business Overview 12.9.2 Promising Vaccines in the Clinical Development

List of Tables Table 4–1: Worldwide Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2013 – 2019 Table 4–2: Worldwide Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2020 – 2027 Table 4–3: Worldwide Influenza Vaccines Market Share (Percent),2013 – 2019 Table 4–4: Worldwide Influenza Vaccines Market Share Forecast (Percent),2020 – 2027 Table 8–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization Table 8–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization Table 8–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization Table 9–1: Merger & Acquisitions in the Influenza Vaccines Market Table 9–2: Collaboration Deal in the Influenza Vaccines Market Table 9–3: Licensing Agreement in the Influenza Vaccines Market Table 9–4: Exclusive Agreement in the Influenza Vaccines Market Table 9–5: Distribution Agreement in the Influenza Vaccines Market Table 11–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development Table 11–2: Seqirus Promising Influenza Vaccines in the Clinical Development Table 12–1: Novavax Promising Influenza Vaccines in the Clinical Development Table 12–2: Biondvax Promising Influenza Vaccines in the Clinical Development Table 12–3: Medicago Promising Influenza Vaccines in the Clinical Development Table 12–4: Moderna Promising Influenza Vaccines in the Clinical Development Table 12–5: Pneumagen Promising Influenza Vaccines in the Clinical Development Table 12–6: Altimmune Promising Influenza Vaccines in the Clinical Development Table 12–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development Table 12–8: FluGen Promising Influenza Vaccines in the Clinical Development Table 12–9: Imutex Promising Influenza Vaccines in the Clinical Development List of Figures Figure 2–1: Worldwide Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 2–2: Worldwide Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027 Figure 3–1: Worldwide Influenza Vaccines Market (Million US$),2013 – 2019 Figure 3–2: Worldwide Influenza Vaccines Market Forecast (Million US$),2020 – 2027 Figure 6–1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 6–2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–3: United States Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–4: United States Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 6–6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–7: Canada Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–8: Canada Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 6–10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–11: Germany Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–12: Germany Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 6–14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–15: France Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–16: France Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 6–18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–19: Italy Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–20: Italy Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 6–22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–23: Spain Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–24: Spain Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019 Figure 6–26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027 Figure 6–27: United Kingdom Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–31: Netherlands Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–35: Sweden Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–39: Denmark Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–43: Poland Influenza Vaccines Revenue Market (Million US$),2013 – 2019 Figure 6–44: Poland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–47: Norway Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–48: Norway Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–51: Finland Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–52: Finland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–55: Ireland Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027 Figure 6–59: Belgium Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027 Figure 6–61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–63: Australia Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–64: Australia Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–67: New Zealand Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027 Figure 6–71: Japan Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–72: Japan Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 6–73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027 Figure 6–75: Brazil Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027 Figure 6–77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027 Figure 6–79: China Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–80: China Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027 Figure 6–81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027 Figure 6–83: India Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–84: India Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027 Figure 6–85: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019 Figure 6–86: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027 Figure 6–87: ROW Influenza Vaccines Market Revenue (Million US$),2013 – 2019 Figure 6–88: ROW Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027 Figure 12–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2019 Figure 12–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027 Figure 12–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2019 Figure 12–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027 Figure 12–3: Seqirus Influenza Vaccines Net Sales Value (Million US$),2013 – 2019 Figure 12–4: Sequirus Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027 Figure 12–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2019 Figure 12–6: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2027